TriSalus Life Sciences, Inc. - Common Stock (TLSI)
5.7500
0.00 (0.00%)
TriSalus Life Sciences, Inc. is a biotechnology company focused on developing innovative therapeutic solutions for cancer patients
The company is committed to transforming the treatment landscape for solid tumors by advancing its proprietary drug delivery technologies and targeting approaches. Through its research and development efforts, TriSalus aims to enhance the efficacy and safety of existing cancer therapies, thereby improving outcomes for patients facing challenging diagnoses. The company's focus on the intersection of immunotherapy and localized delivery positions it to address unmet needs in oncology, aiming to improve patient quality of life and survival rates.
TLSI stock results show that TriSalus Life Sciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Companies Reporting Before The Bell • Mach Natural Resources (NYSEMNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.
U.S. stocks traded down this morning, with the Nasdaq Composite falling more than 101 points on Friday. Here are some big stocks recording gains in today’s session.
U.S. stocks traded down this morning with the Nasdaq Composite falling more than 101 points on Friday. The Dow traded down 0.23% to 34,396.96 while the NASDAQ fell 0.91% to 13,196.22. The S&P 500 also fell, dropping 0.45% to 4,350.51.
